Cited 8 times in
Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이무상 | - |
dc.contributor.author | 정병하 | - |
dc.contributor.author | 홍성준 | - |
dc.date.accessioned | 2017-05-04T07:35:41Z | - |
dc.date.available | 2017-05-04T07:35:41Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 0919-8172 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/147516 | - |
dc.description.abstract | BACKGROUND: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective alpha1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH. METHODS: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment. RESULTS: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (> or =65 years, n = 100) and younger (45-64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth. CONCLUSIONS: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Science Asia | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF UROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adrenergic alpha-Antagonists/therapeutic use* | - |
dc.subject.MESH | Age Factors | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Doxazosin/therapeutic use* | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypertension/complications | - |
dc.subject.MESH | Hypertension/drug therapy | - |
dc.subject.MESH | Korea | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Prostatic Hyperplasia/complications | - |
dc.subject.MESH | Prostatic Hyperplasia/drug therapy* | - |
dc.subject.MESH | Quality of Life | - |
dc.subject.MESH | Severity of Illness Index | - |
dc.subject.MESH | Single-Blind Method | - |
dc.title | Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice | - |
dc.type | Article | - |
dc.publisher.location | Australia | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | BYUNG HA CHUNG | - |
dc.contributor.googleauthor | SUNG JOON HONG | - |
dc.contributor.googleauthor | MOO SANG LEE | - |
dc.identifier.doi | 10.1111/j.1442-2042.2005.00998.x | - |
dc.contributor.localId | A02763 | - |
dc.contributor.localId | A03607 | - |
dc.contributor.localId | A04402 | - |
dc.relation.journalcode | J01169 | - |
dc.identifier.eissn | 1442-2042 | - |
dc.identifier.pmid | 15733110 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1442-2042.2005.00998.x/abstract | - |
dc.subject.keyword | drug therapy | - |
dc.subject.keyword | hypertension | - |
dc.subject.keyword | Korea | - |
dc.subject.keyword | prostatic hyperplasia | - |
dc.contributor.alternativeName | Lee, Moo Sang | - |
dc.contributor.alternativeName | Chung, Byung Ha | - |
dc.contributor.alternativeName | Hong, Sung Joon | - |
dc.citation.volume | 12 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 159 | - |
dc.citation.endPage | 165 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF UROLOGY, Vol.12(2) : 159-165, 2005 | - |
dc.date.modified | 2017-05-04 | - |
dc.identifier.rimsid | 40294 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.